Off-Label Use of Bedaquiline in Children and Adolescents with Multidrug-Resistant Tuberculosis

Off-Label Use of Bedaquiline in Children and Adolescents with Multidrug-Resistant Tuberculosis

We describe 27 children and adolescents <18 years of age who received bedaquiline during treatment for multidrug-resistant tuberculosis. We report good treatment responses and no cessation attributable to adverse effects. Bedaquiline could be considered for use with this age group for multidrug-r...

Full description

Bibliographic Details
Main Authors: Jay Achar, Cathy Hewison, Ana P. Cavalheiro, Alena Skrahina, Junia Cajazeiro, Parpieva Nargiza, Krzysztof Herboczek, Assliddin S. Rajabov, Jennifer Hughes, Gabriella Ferlazzo, James A. Seddon, Philipp du Cros
Format: Article
Language:English
Published: Centers for Disease Control and Prevention 2017-10-01
Series:Emerging Infectious Diseases
Subjects:
MDR TB
XDR TB
pediatric
treatment
bedaquiline
tuberculosis
Online Access:https://wwwnc.cdc.gov/eid/article/23/10/17-0303_article

Internet

https://wwwnc.cdc.gov/eid/article/23/10/17-0303_article

Similar Items